Stockscreener 앱 받기
19.80
3.61%
0.69
시간 외 거래:
18.88
-0.92
-4.65%
전일 마감가:
$19.11
열려 있는:
$19.13
하루 거래량:
75,062
Relative Volume:
0.80
시가총액:
$473.15M
수익:
$26.00M
순이익/손실:
$-219.71M
주가수익비율:
-
EPS:
-
순현금흐름:
$-51.37M
1주 성능:
-11.41%
1개월 성능:
-19.25%
6개월 성능:
-22.66%
1년 성능:
+0.00%
1일 변동 폭
$19.05
$20.34
1주일 범위
$18.85
$22.90
52주 변동 폭
$11.66
$42.60
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
617-923-1400
주소
704 QUINCE ORCHARD RD, GAITHERSBURG
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - The Manila Times
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance
Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat
30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN
Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa
Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World
Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat
Cartesian therapeutics director Timothy Springer buys $4.29m in stock - Investing.com
Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpHere's Why - MarketBeat
Cartesian Therapeutics Inc [NASDAQ: RNAC] Sees Increase in Stock Value - Knox Daily
Cartesian Therapeutics Inc (RNAC) Stock: A Year of Highs and Lows - The InvestChronicle
Emcore Corp. [EMKR] Records 50-Day SMA of $1.18 - Knox Daily
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Point72 DIFC Ltd Invests $47,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Logos Global Management LP Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Point72 Asia Singapore Pte. Ltd. Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Logos Global Management LP Purchases Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
1,725 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Acquired by Point72 DIFC Ltd - Defense World
Rhumbline Advisers Sells 121,396 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Rhumbline Advisers Has $229,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Mizuho affirms Outperform on Cartesian Therapeutics stock, highlights Descartes-08’s competitive edge - Investing.com Canada
Logos Global Management LP Invests $2.43 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com Australia
Logos Global Management LP Buys Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Bank of New York Mellon Corp Has $538,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance - Investing.com
Cartesian Therapeutics Puts Talent and Innovation at the Heart of the Organization - BioBuzz
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics Receives FDA Rare Pediatric Disease - GlobeNewswire
FDA grants rare pediatric status for Cartesian’s Descartes-08 - The Pharma Letter
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment - MarketWatch
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis - Yahoo Finance
Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma - CGTLive™
Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewswire
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics shares maintain Buy rating as new trial kicks off - Investing.com Canada
Cartesian advances new mRNA therapy into Phase 1 trial - Investing.com India
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cartesian Therapeutics Inc 주식 (RNAC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | Director |
Oct 04 '24 |
Buy |
22.58 |
80,301 |
1,813,010 |
8,023,766 |
| SPRINGER TIMOTHY A | Director |
Oct 02 '24 |
Buy |
17.38 |
5,514 |
95,822 |
7,823,559 |
| SPRINGER TIMOTHY A | Director |
Aug 12 '24 |
Buy |
12.72 |
8,016 |
101,968 |
11,509 |
| BARABE TIMOTHY C | Director |
Aug 12 '24 |
Buy |
12.70 |
7,500 |
95,250 |
21,766 |
| SPRINGER TIMOTHY A | Director |
Mar 08 '24 |
Buy |
0.66 |
4,800 |
3,187 |
95,218 |
| SPRINGER TIMOTHY A | Director |
Mar 13 '24 |
Buy |
0.58 |
3,200 |
1,868 |
100,818 |
| SPRINGER TIMOTHY A | Director |
Feb 07 '24 |
Buy |
0.66 |
2,400 |
1,575 |
90,418 |
| SPRINGER TIMOTHY A | Director |
Mar 14 '24 |
Buy |
0.53 |
2,000 |
1,061 |
102,818 |
| SPRINGER TIMOTHY A | Director |
Mar 11 '24 |
Buy |
0.65 |
1,200 |
785 |
96,418 |
| SPRINGER TIMOTHY A | Director |
Mar 12 '24 |
Buy |
0.61 |
1,200 |
735 |
97,618 |
2.02%
0.47%
자본화:
|
볼륨(24시간):